EGFR and lung adenocarcinoma: Consistent with previous reports [26,27], we observed the TP53 mutations were poor RFS-related factors for recurrence in stage IB–IIIA tumors with EGFR-mutated lung adenocarcinoma (Figure 3e; p = 0.01).